Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Comparing VMAT-2 Inhibitor Options for Tardive Dyskinesia Treatment
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
hoberg
Videos
Tardive Dyskinesia Refresher: Causes, Identification, and Impact
07/10/2024
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox...
07/10/2024
Psych Congress Network

Advertisement

amber hoberg
Videos
Tardive Dyskinesia Refresher: Causes, Identification, and Impact
07/10/2024
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox with information on TD's impact on patients and the essential requirements for successful treatment.
Refresh your clinical toolbox...
07/10/2024
Psych Congress Network
Julie Carbray, PhD
Videos
Avoiding Cardiometabolic Symptoms in Conventional Bipolar Disorder Treatment
07/10/2024
In this video, Dr Carbray explores the adverse cardiometabolic effects of conventional treatments, including weight gain, impaired glucose, and elevated cholesterol, and their impact on patient outcomes.
In this video, Dr Carbray explores the adverse cardiometabolic effects of conventional treatments, including weight gain, impaired glucose, and elevated cholesterol, and their impact on patient outcomes.
In this video, Dr Carbray...
07/10/2024
Psych Congress Network
chepke
Videos
Differential Diagnosis of Tardive Dyskinesia and Other Movement Disorders
07/09/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares...
07/09/2024
Psych Congress Network

Advertisement

Chepke
Videos
Differential Diagnosis of Tardive Dyskinesia and Other Movement Disorders
07/09/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Craig Chepke, MD, DFAPA, shares...
07/09/2024
Psych Congress Network
chepke
Videos
Differential Diagnosis of Tardive Dyskinesia and Drug-Induced Parkinsonism
07/02/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders such as drug-induced Parkinsonism.
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders such as drug-induced Parkinsonism.
Craig Chepke, MD, DFAPA, shares...
07/02/2024
Psych Congress Network

Advertisement

Dr Rakesh Jain
Videos
Emerging Therapies in Bipolar Disorder Treatment
07/02/2024
Learn about the safety and efficacy of these new agents and gain insights into improving diagnosis and treatment strategies. 
Learn about the safety and efficacy of these new agents and gain insights into improving diagnosis and treatment strategies. 
Learn about the safety and...
07/02/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use